Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury (TACROVID)

Catalan Institute of Health

Status and phase: Unknown; Phase 3

Conditions: COVID-19; Lung Injury

Treatments: Drug: Tacrolimus; Drug: Methylprednisolone

Study type: Interventional

Funder types: Other

Identifiers

NCT04341038

TACRO-BELL-COVID

2020-001445-39 (EudraCT Number)

Details and patient eligibility

About

The primary objective of the study is to evaluate the days until reaching clinical stability after starting randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury.

Full description

Unfortunately, the treatment of COVID-19 disease is still based on life support therapies. Nowadays, there is no scientific evidence from clinical trials regarding the efficacy or safety of different drugs to treat COVID-19 patients, despite some of them evolving to fatal severe lung injury due to important inflammatory process secondary to pro-inflammatory cytokines. Interestingly, Tacrolimus has been shown to inhibit both pro-inflammatory cytokines and, also, human coronavirus SARS-Cov replication, but it has not specifically been tested in COVID-19 patients.

Our working hypothesis is that severe SARS-CoV-2 (COVID-19) pneumonia is secondary to a deleterious inflammatory process; so, the use of Methylprednisolone pulses and Tacrolimus in hospitalized severe COVID-19 lung injury patients might have a positive clinical effect.

Given the COVID-19 current health emergency, this study could provide useful evidence to treat some COVID-19 patients with Methylprednisolona and Tacrolimus, which might represent a new therapeutic option for them. Tacrolimus is a drug with more than 20 years of experience, and therefore, its side effects are well known and usually reversible. In addition, since tacrolimus is a low-cost and easy to produce at large-scale drug, it could be used to treat a large number of patients. The administration of this drugs could not only decrease mortality secondary to lung involvement by COVID-19, but also decrease the excessive burden of care that intensive care units are bearing.

Enrollment: 84 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 infection confirmed by PCR
• New onset radiological infiltrates
• Respiratory failure (PaO2 / FiO2 <300 or satO2 / FiO2 <220)
• PCR>100 mg/L and/or D-Dimer>1000 µg/L and/or Ferritin>1000 ug/L
• Informed consent.

Exclusion criteria

• Life expectancy ≤ 24h
• Glomerular filtration ≤ 30 ml / min / 1.73 m2
• Leukopenia ≤ 4000 cells / µL
• Concomitant potentially serious infections.
• Contraindication for the use of tacrolimus according to the specifications of the product
• Known adverse reactions to treatment
• Have participated in a clinical trial in the last 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

84 participants in 2 patient groups

Intervention

Experimental group

Description:

Methylprednisolone pulses 120mg/day for 3 consecutive days (if they were not previously administered) with Tacrolimus at the necessary dose to achieve plasma levels of 8-10 ng/ml. In addition, these patients can receive all the treatments considered necessary for their clinical management.

Treatment:

Drug: Methylprednisolone

Drug: Tacrolimus

Usual care

No Intervention group

Description:

These patients can receive all the treatments considered necessary for their clinical management, except cyclosporine and tacrolimus.